Sobi (Swedish Orphan Biovitrum AB)
(https://synagis.com) 📸 Data Snapshot: June 19, 2026
Semantic Coherence — The Lens
Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.
Semantic Coherence
Homepage promise vs. Sub-page reality.
15
Impact Weight: 20 / 100
75% Reputation
There is a notable technical drift across the crawled pages: the ‘pipeline’ and ‘careers’ sub-pages (slot_rank 2 and 3) return the exact same body content and H1 as the homepage. This creates a disconnect where the user expects specific pipeline or career data but is served a generic corporate landing page, indicating a failure in the content delivery architecture for this domain.
Semantic Coherence is read from the heading hierarchy first: what each page announces in its H1 and headings, then whether the body actually delivers on it. Below is the structure the engine mapped, followed by the clean text to check for drift between promise and reality.
🏗️ Semantic Structure — heading hierarchy & page identity (the promise the page makes)
HOMEPAGE Sobi – Transforming the lives of people with rare diseases (https://synagis.com)
Title
Sobi – Transforming the lives of people with rare diseases
Meta
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Learn more about us here.
H1 We transformeveryday life for people living with rare diseases
H3 Innovative medicines in the pipeline
H3 Financial reports
H3 Press releases
H3 Focus on sustainability
H3 Focus on Rare diseases
H3 A new therapy’s path to the patient
H3 Our stories
H3 Head office
H3 Careers
H5 Living with Diffuse Large B-Cell Lymphoma
H5 Diagnose Diffuse Large B-Cell Lymphoma
H5 A decade of dedication: Transforming haemophilia care through global collaboration
H5 Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program
H5 Diagnosis and donations to enable sustainable care in Cambodia
H6 © Sobi – Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321
REPEATED_BODY Sobi – Transforming the lives of people with rare diseases (https://synagis.com/middle-east/en/)
Title
Sobi – Transforming the lives of people with rare diseases
Meta
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Learn more about us here.
H1 We transformeveryday life for people living with rare diseases
H3 Innovative medicines in the pipeline
H3 Financial reports
H3 Press releases
H3 Focus on sustainability
H3 Focus on Rare diseases
H3 A new therapy’s path to the patient
H3 Our stories
H3 Head office
H3 Careers
H5 Living with Diffuse Large B-Cell Lymphoma
H5 Diagnose Diffuse Large B-Cell Lymphoma
H5 A decade of dedication: Transforming haemophilia care through global collaboration
H5 Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program
H5 Diagnosis and donations to enable sustainable care in Cambodia
H6 © Sobi – Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321
NAV_HEADING_REPEATED_BODY Sobi – Transforming the lives of people with rare diseases (https://synagis.com/en/pipeline/)
Title
Sobi – Transforming the lives of people with rare diseases
Meta
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Learn more about us here.
H1 We transformeveryday life for people living with rare diseases
H3 Innovative medicines in the pipeline
H3 Financial reports
H3 Press releases
H3 Focus on sustainability
H3 Focus on Rare diseases
H3 A new therapy’s path to the patient
H3 Our stories
H3 Head office
H3 Careers
H5 Living with Diffuse Large B-Cell Lymphoma
H5 Diagnose Diffuse Large B-Cell Lymphoma
H5 A decade of dedication: Transforming haemophilia care through global collaboration
H5 Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program
H5 Diagnosis and donations to enable sustainable care in Cambodia
H6 © Sobi – Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321
NAV_HEADER_HEADING_REPEATED_BODY_FOOTER Sobi – Transforming the lives of people with rare diseases (https://synagis.com/en/careers/)
Title
Sobi – Transforming the lives of people with rare diseases
Meta
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Learn more about us here.
H1 We transformeveryday life for people living with rare diseases
H3 Innovative medicines in the pipeline
H3 Financial reports
H3 Press releases
H3 Focus on sustainability
H3 Focus on Rare diseases
H3 A new therapy’s path to the patient
H3 Our stories
H3 Head office
H3 Careers
H5 Living with Diffuse Large B-Cell Lymphoma
H5 Diagnose Diffuse Large B-Cell Lymphoma
H5 A decade of dedication: Transforming haemophilia care through global collaboration
H5 Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program
H5 Diagnosis and donations to enable sustainable care in Cambodia
H6 © Sobi – Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321
📝 The Narrative — clean text per page (homepage promise vs. sub-page reality)
HOMEPAGE (https://synagis.com) Sobi – Transforming the lives of people with rare diseases
[H1] We transformeveryday life for people living with rare diseases More about us We are unlocking the potential of breakthrough therapies Join us OUR SCIENCE | R&D [H3] Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE [H3] Financial reports Sobi intends to publish its Q2 2026 report on 16 July 2026.Aide memoire Financial reports MEDIA | PRESS RELEASES [H3] Press releases 11 June, 2026 08:00 Sobi to present new clinical and real-world data at EHA 2026 in Stockholm 1 June, 2026 10:00 Sobi to present new data on pegcetacoplan at ERA 2026 Learn more News [H3] Focus on sustainability Sobi celebrates meaningful progress on its climate journey – from validated science-based targets to rising use of renewable electricity and fossil-free car fleets across several countries. Our climate progress RARE DISEASES [H3] Focus on Rare diseases More than 10,000 rare diseases have been identified, with more being discovered every day. While many rare diseases are very uncommon, together they affect 400 million people worldwide. Rare diseases INNOVATIVE TREATMENTS [H3] A new therapy’s path to the patient Bringing new therapies to patients involves navigating long timelines and inherent risks, making it a complex and costly endeavor. Discover how we prioritise patient access to treatment while addressing these development challenges. From lab to patient [H3] Our stories At Sobi, we are dedicated to transforming the lives of people with rare and debilitating diseases. Meet some of the people who inspire us.Their real-life experiences and stories reinforce our commitment to patients. Read the stories Haematology [H5] Living with Diffuse Large B-Cell Lymphoma Haematology [H5] Diagnose Diffuse Large B-Cell Lymphoma Haemophilia [H5] A decade of dedication: Transforming haemophilia care through global collaboration Haemophilia [H5] Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program Haematology [H5] Diagnosis and donations to enable sustainable care in Cambodia Share price Loading... Share information [IMG: Sobi_HQ_office_building-cut.jpg] [H3] Head office [email protected] +46 8 697 20 00 Visiting address: Norra Stationsgatan 93A Stockholm, Sweden Global contacts [H3] Careers Take a look at our job opportunities. Join us English Swedish Global Global Global contacts Europe Austria Belgium NL Belgium FR Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Malta Norway Poland Portugal Romania Russia Slovakia Slovenia Spain Sweden Switzerland DE Switzerland FR The Netherlands Turkey United Kingdom Middle East & Africa Algeria Bahrain Egypt Iraq Jordan Kuwait Lebanon Libya Middle East Morocco Qatar Oman Saudi Arabia Tunisia United Arab Emirates Asia Pacific Australia China Japan North America USA Canada Close Close
3733 chars
SUB-PAGE (https://synagis.com/middle-east/en/) Sobi – Transforming the lives of people with rare diseases
[H1] We transformeveryday life for people living with rare diseases More about us We are unlocking the potential of breakthrough therapies Join us OUR SCIENCE | R&D [H3] Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE [H3] Financial reports Sobi intends to publish its Q2 2026 report on 16 July 2026.Aide memoire Financial reports MEDIA | PRESS RELEASES [H3] Press releases 11 June, 2026 08:00 Sobi to present new clinical and real-world data at EHA 2026 in Stockholm 1 June, 2026 10:00 Sobi to present new data on pegcetacoplan at ERA 2026 Learn more News [H3] Focus on sustainability Sobi celebrates meaningful progress on its climate journey – from validated science-based targets to rising use of renewable electricity and fossil-free car fleets across several countries. Our climate progress RARE DISEASES [H3] Focus on Rare diseases More than 10,000 rare diseases have been identified, with more being discovered every day. While many rare diseases are very uncommon, together they affect 400 million people worldwide. Rare diseases INNOVATIVE TREATMENTS [H3] A new therapy’s path to the patient Bringing new therapies to patients involves navigating long timelines and inherent risks, making it a complex and costly endeavor. Discover how we prioritise patient access to treatment while addressing these development challenges. From lab to patient [H3] Our stories At Sobi, we are dedicated to transforming the lives of people with rare and debilitating diseases. Meet some of the people who inspire us.Their real-life experiences and stories reinforce our commitment to patients. Read the stories Haematology [H5] Living with Diffuse Large B-Cell Lymphoma Haematology [H5] Diagnose Diffuse Large B-Cell Lymphoma Haemophilia [H5] A decade of dedication: Transforming haemophilia care through global collaboration Haemophilia [H5] Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program Haematology [H5] Diagnosis and donations to enable sustainable care in Cambodia Share price Loading... Share information [IMG: Sobi_HQ_office_building-cut.jpg] [H3] Head office [email protected] +46 8 697 20 00 Visiting address: Norra Stationsgatan 93A Stockholm, Sweden Global contacts [H3] Careers Take a look at our job opportunities. Join us English Swedish Global Global Global contacts Europe Austria Belgium NL Belgium FR Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Malta Norway Poland Portugal Romania Russia Slovakia Slovenia Spain Sweden Switzerland DE Switzerland FR The Netherlands Turkey United Kingdom Middle East & Africa Algeria Bahrain Egypt Iraq Jordan Kuwait Lebanon Libya Middle East Morocco Qatar Oman Saudi Arabia Tunisia United Arab Emirates Asia Pacific Australia China Japan North America USA Canada Close Close
3733 chars
SUB-PAGE (https://synagis.com/en/pipeline/) Sobi – Transforming the lives of people with rare diseases
[H1] We transformeveryday life for people living with rare diseases More about us We are unlocking the potential of breakthrough therapies Join us OUR SCIENCE | R&D [H3] Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE [H3] Financial reports Sobi intends to publish its Q2 2026 report on 16 July 2026.Aide memoire Financial reports MEDIA | PRESS RELEASES [H3] Press releases 11 June, 2026 08:00 Sobi to present new clinical and real-world data at EHA 2026 in Stockholm 1 June, 2026 10:00 Sobi to present new data on pegcetacoplan at ERA 2026 Learn more News [H3] Focus on sustainability Sobi celebrates meaningful progress on its climate journey – from validated science-based targets to rising use of renewable electricity and fossil-free car fleets across several countries. Our climate progress RARE DISEASES [H3] Focus on Rare diseases More than 10,000 rare diseases have been identified, with more being discovered every day. While many rare diseases are very uncommon, together they affect 400 million people worldwide. Rare diseases INNOVATIVE TREATMENTS [H3] A new therapy’s path to the patient Bringing new therapies to patients involves navigating long timelines and inherent risks, making it a complex and costly endeavor. Discover how we prioritise patient access to treatment while addressing these development challenges. From lab to patient [H3] Our stories At Sobi, we are dedicated to transforming the lives of people with rare and debilitating diseases. Meet some of the people who inspire us.Their real-life experiences and stories reinforce our commitment to patients. Read the stories Haematology [H5] Living with Diffuse Large B-Cell Lymphoma Haematology [H5] Diagnose Diffuse Large B-Cell Lymphoma Haemophilia [H5] A decade of dedication: Transforming haemophilia care through global collaboration Haemophilia [H5] Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program Haematology [H5] Diagnosis and donations to enable sustainable care in Cambodia Share price Loading... Share information [IMG: Sobi_HQ_office_building-cut.jpg] [H3] Head office [email protected] +46 8 697 20 00 Visiting address: Norra Stationsgatan 93A Stockholm, Sweden Global contacts [H3] Careers Take a look at our job opportunities. Join us English Swedish Global Global Global contacts Europe Austria Belgium NL Belgium FR Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Malta Norway Poland Portugal Romania Russia Slovakia Slovenia Spain Sweden Switzerland DE Switzerland FR The Netherlands Turkey United Kingdom Middle East & Africa Algeria Bahrain Egypt Iraq Jordan Kuwait Lebanon Libya Middle East Morocco Qatar Oman Saudi Arabia Tunisia United Arab Emirates Asia Pacific Australia China Japan North America USA Canada Close Close
3733 chars
SUB-PAGE (https://synagis.com/en/careers/) Sobi – Transforming the lives of people with rare diseases
[H1] We transformeveryday life for people living with rare diseases More about us We are unlocking the potential of breakthrough therapies Join us OUR SCIENCE | R&D [H3] Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE [H3] Financial reports Sobi intends to publish its Q2 2026 report on 16 July 2026.Aide memoire Financial reports MEDIA | PRESS RELEASES [H3] Press releases 11 June, 2026 08:00 Sobi to present new clinical and real-world data at EHA 2026 in Stockholm 1 June, 2026 10:00 Sobi to present new data on pegcetacoplan at ERA 2026 Learn more News [H3] Focus on sustainability Sobi celebrates meaningful progress on its climate journey – from validated science-based targets to rising use of renewable electricity and fossil-free car fleets across several countries. Our climate progress RARE DISEASES [H3] Focus on Rare diseases More than 10,000 rare diseases have been identified, with more being discovered every day. While many rare diseases are very uncommon, together they affect 400 million people worldwide. Rare diseases INNOVATIVE TREATMENTS [H3] A new therapy’s path to the patient Bringing new therapies to patients involves navigating long timelines and inherent risks, making it a complex and costly endeavor. Discover how we prioritise patient access to treatment while addressing these development challenges. From lab to patient [H3] Our stories At Sobi, we are dedicated to transforming the lives of people with rare and debilitating diseases. Meet some of the people who inspire us.Their real-life experiences and stories reinforce our commitment to patients. Read the stories Haematology [H5] Living with Diffuse Large B-Cell Lymphoma Haematology [H5] Diagnose Diffuse Large B-Cell Lymphoma Haemophilia [H5] A decade of dedication: Transforming haemophilia care through global collaboration Haemophilia [H5] Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program Haematology [H5] Diagnosis and donations to enable sustainable care in Cambodia Share price Loading... Share information [IMG: Sobi_HQ_office_building-cut.jpg] [H3] Head office [email protected] +46 8 697 20 00 Visiting address: Norra Stationsgatan 93A Stockholm, Sweden Global contacts [H3] Careers Take a look at our job opportunities. Join us English Swedish Global Global Global contacts Europe Austria Belgium NL Belgium FR Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Malta Norway Poland Portugal Romania Russia Slovakia Slovenia Spain Sweden Switzerland DE Switzerland FR The Netherlands Turkey United Kingdom Middle East & Africa Algeria Bahrain Egypt Iraq Jordan Kuwait Lebanon Libya Middle East Morocco Qatar Oman Saudi Arabia Tunisia United Arab Emirates Asia Pacific Australia China Japan North America USA Canada Close Close
3733 chars
Explore the other reputation pillars for Sobi (Swedish Orphan Biovitrum AB)
Analysis Disclosure & Source Attribution
This page presents a snapshot of public data from Sobi (Swedish Orphan Biovitrum AB), captured on June 19, 2026, to show how machine logic reads Semantic Coherence signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Sobi (Swedish Orphan Biovitrum AB): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://synagis.com to view the most current version of its content and see directly what this company is about and what it offers.